Neufeldt, Dimyana
Schmidt, Arne
Mohr, Elisa
Lu, Dongchao
Chatterjee, Shambhabi
Fuchs, Maximilian
Xiao, Ke
Pan, Wen
Cushman, Sarah
Jahn, Christopher
Juchem, Malte
Hunkler, Hannah Jill
Cipriano, Giuseppe
Jürgens, Bjarne
Schmidt, Kevin
Groß, Sonja
Jung, Mira
Hoepfner, Jeannine
Weber, Natalie
Foo, Roger
Pich, Andreas
Zweigerdt, Robert
Kraft, Theresia
Thum, Thomas http://orcid.org/0000-0003-4360-1511
Bär, Christian
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (TRR267, TRR267, ZW 64/4-2, KR1187/21-2)
HORIZON EUROPE European Research Council (REVERSE)
Medizinische Hochschule Hannover (MHH)
Article History
Received: 10 May 2023
Revised: 6 March 2024
Accepted: 26 March 2024
First Online: 19 April 2024
Declarations
:
: T.T. is a founder and shareholder of Cardior Pharmaceuticals GmbH (outside the topic of this paper). D.L., C.B., T.T. have filed a patent on the use of circular RNAs for the treatment of cardiotoxicity.